Business · 20/11/20261 min read
Novo's Sogroya® receives FDA approval as the first and only once-weekly, long-acting growth hormone for children with Turner Syndrome (TS)
Summary
Sogroya® is a once-weekly treatment option for appropriate children 2.5 and older, offering an alternative to once-daily therapy, which may help address the common challenge of non-adherence associated with daily injections1 Approval based on results from the pivotal REAL8 clinical trial...